Intervention Protocol

You have free access to this content

Pharmacotherapy for bipolar disorder in older people

  1. Akshya Vasudev1,*,
  2. Alan J Thomas2,
  3. Heinz Grunze3

Editorial Group: Cochrane Depression, Anxiety and Neurosis Group

Published Online: 30 APR 2013

DOI: 10.1002/14651858.CD010495


How to Cite

Vasudev A, Thomas AJ, Grunze H. Pharmacotherapy for bipolar disorder in older people (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010495. DOI: 10.1002/14651858.CD010495.

Author Information

  1. 1

    London Health Sciences Centre, Victoria Hospital, University of Western Ontario, London, Ontario, Canada

  2. 2

    Newcastle University, Institute for Ageing and Health, Newcastle Upon Tyne, UK

  3. 3

    Newcastle University, Institute of Neuroscience, Department of Psychiatry, Newcastle upon Tyne, Tyne and Wear, UK

*Akshya Vasudev, University of Western Ontario, London Health Sciences Centre, Victoria Hospital, 800 Commissioners Road East, PO BOX 5010, London, Ontario, Canada. akshya.vasudev@uwo.ca. akshya38@hotmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 30 APR 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

1. To determine the efficacy of any pharmacotherapeutic intervention compared to placebo or an alternative drug:

1.1 in alleviating acute manic episodes of bipolar disorder in the older person;
1.2 in alleviating depressive symptoms in acute episodes of bipolar disorder in the older person;
1.3 in alleviating mixed affective symptoms in acute episodes of bipolar disorder in the older person.

2. To review the acceptability of treatment with medications to patients, measured by numbers and reasons for dropping out of trials, compliance, and by reference to patients' expressed views regarding treatment.

3. To investigate the adverse effects of pharmacological treatments including the general prevalence of adverse effects. All adverse effects documented in the included studies will be extracted where possible.

4. To determine the overall mortality rates on various pharmacological treatments.

5. To prevent relapse of the illness in the medium or long term.